Reactive astrocytes and α1-antichymotrypsin in Alzheimer's disease

Neurobiology of Aging

Volumn 22, Issue 6, 2001, Pages 931-936

  Abraham, Carmela R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1 antichymotrypsin; Acute phase proteins; Amyloid protein; Animal models of AD; Apolipoprotein E; Cytokines; Neuroinflammation

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PROTEINASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BIOCHEMISTRY; BRAIN; CELL ACTIVATION; CLEARANCE; DISEASE ASSOCIATION; GENETICS; HUMAN; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SENILE PLAQUE; TRANSGENIC MOUSE; ANIMAL; PATHOLOGY; PHYSIOLOGY; REVIEW;

ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; ANIMAL; ASTROCYTES; HUMAN; SENILE PLAQUES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035543191     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(01)00302-5     Document Type: Article

References (56)

1. Alpha 1-antichymotrypsin inhibits A beta degradation in vitro, and in vivo
2. Immunohistochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease
3. Alpha 1-antichymotrypsin is present together with the beta-protein in monkey brain amyloid deposits
4. α1-antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell localization of of α1-antichymotrypsin
5. Antiinflammatory therapy for Alzheimer's disease
6. Alpha-1-antichymotrypsin interaction with A beta (1-40) inhibits fibril formation but does not affect the peptide toxicity
7. Interaction of nascent apoE2, apoE3, and apoE4 isoforms expressed in mammalian cells with amyloid peptide β (1-40). Relevance to Alzheimer's disease
8. Patterns of gliosis in Alzheimer's disease and aging cerebrum
9. Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta
10. Neurodegenerative Alzheimer-like pathology in PDAPP 717V → F transgenic mice
11. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1
12. General and dramatic glial reaction in Alzheimer brain
13. Secretases as therapeutic target for treatment of Alzheimer's disease
14. Molecular profile of reactive astrocytes-implications for their role in neurologic disease
15. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study
16. Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation
17. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific, and induces fibril disaggregation in vitro
18. Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease
19. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
20. Alzheimer's disease, and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
21. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease
22. An immunohistochemical quantification of fibrous astrocytes in the aging human cerebral cortex
23. Transgenic mice expressing Alzheimer amyloid precursor proteins
24. A specific structural interaction of Alzheimer's peptide A beta 1-42 with alpha 1-antichymotrypsin
25. Targetting small Aβ oligomers: The solution to an Alzheimer's disease conundrum?
26. Developmental expression of alpha 1-antichymotrypsin in brain may be related to astrogliosis
27. Oncostatin M, and the interleukin-6 (IL-6), and soluble IL-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes
28. Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha-1-antichymotrypsin gene in human astrocytes
29. Gene-expression profile of the ageing brain in mice
30. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
31. Early onset and topographical distribution of hypertrophied astrocytes in hippocampus of aging rats: A quantitative study
32. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red
33. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease
34. Alzheimer A beta neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides
35. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments
36. Apolipoprotein E: From atherosclerosis to Alzheimer's disease, and beyond
37. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease
38. Glial cell reactions in neurodegenerative diseases: Pathophysiology and therapeutic interventions
39. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
40. Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice
41. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease
42. Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA
43. Apolipoprotein E: A pharmacogenetic target for the treatment of Alzheimer's disease
44. Gliosis following CNS injury: The anatomy of astrocytic scars and their influences on axonal elongation
45. The astrocytic scar as an impediment to regeneration in the central nervous system
46. Overexpression of s100beta in Down's syndrome: Correlation with patient age and with beta-amyloid deposition
47. Distribution pattern and functional state of alpha 1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease. A immunohistochemical study with monoclonal antibodies against native and inactivated alpha 1-antichymotrypsin
48. The role of apolipoprotein E in Alzheimer's disease: Pharmacogenomic target selection
49. Alzheimer's disease: Genes, proteins, and therapy
50. Astrocytic hypertrophy and altered GFAP degradation with age in subcortical white matter of the rhesus monkey
51. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease
52. Anti-inflammatory drugs, and Alzheimer's disease
53. Apolipoprotein E: A pathological chaperone protein in patients with cerebral, and systemic amyloid
54. Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation
55. The pathogenesis of Alzheimer's disease. Is amyloid beta-protein the beginning or the end?
56. The role of A beta 42 in Alzheimer's disease